EcoDrugPlus

Sphingosine Kinase 2

Ensembl ID : ENSLCRG00005005038
Gene Symbol: SPHK2
2 Cross references
200 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSLCRG00005016200
Gene Symbol: S1PR1
3 Cross references
200 Possible Orthologues:

Spleen Tyrosine Kinase

Ensembl ID : ENSLCRG00005022703
Gene Symbol: SYK
3 Cross references
200 Possible Orthologues:

Steroid 17-Alpha-Hydroxylase/17,20 Lyase

Ensembl ID : ENSLCRG00005018139
Gene Symbol: LOC104935158
3 Cross references
210 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2b

Ensembl ID : ENSLCRG00005004580
Gene Symbol: SRD5A2B
3 Cross references
191 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSLCRG00005013066
Gene Symbol: SOAT1
3 Cross references
210 Possible Orthologues:

Substance-P Receptor

Ensembl ID : ENSLCRG00005003894
Gene Symbol: LOC104938765
3 Cross references
193 Possible Orthologues:

Tachykinin Receptor 2

Ensembl ID : ENSLCRG00005016817
Gene Symbol: TACR2
3 Cross references
199 Possible Orthologues:

Tachykinin Receptor 3

Ensembl ID : ENSLCRG00005008938
Gene Symbol: TACR3
3 Cross references
208 Possible Orthologues:

Tachykinin Receptor 3-Like

Ensembl ID : ENSLCRG00005013482
Gene Symbol: TACR3L
3 Cross references
218 Possible Orthologues:

Telomerase Reverse Transcriptase

Ensembl ID : ENSLCRG00005012654
Gene Symbol: TERT
3 Cross references
189 Possible Orthologues:

Thromboxane A Synthase 1 (Platelet)

Ensembl ID : ENSLCRG00005013282
Gene Symbol: TBXAS1
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).